FLGT

In the past six months (April 2026 - October 2026), Fulgent Genetics' stock experienced significant volatility and declines. On February 27, 2026, the stock plummeted approximately 38.1% following its Q4 2025 earnings report and lower-than-expected 2026 guidance, primarily due to its largest customer moving a significant volume of work in-house, which accounted for 22% of total revenue in 2025. In March 2026, law firms initiated investigations into potential securities fraud. For Q1 2026, reported May 1, 2026, revenue was $71.1 million (down 3.2% year-over-year) and the company reported a net loss of $24.8 million. On June 1, 2026, Fulgent presented updated FID-007 data at ASCO 2026, showing an objective response rate of 61.9% for a therapeutic development candidate for head and neck cancer. Q2 2026 earnings, reported July 30, 2026, showed revenue of $85.4 million and an EPS of -$0.58, both missing analyst estimates, leading to an approximately 18% stock drop. The company also revised its full-year 2026 revenue guidance downwards to $330-$340 million from an earlier $350 million, citing processing delays. Fulgent repurchased 2.6 million shares for $40.1 million in Q1 2026 and approximately 1.5 million shares for $23.8 million in Q2 2026. On March 17, 2026, Fulgent acquired Bako Diagnostics and StrataDx to expand its pathology laboratory services.